119-HR-7871 Journalist Public Summary
119 · HR 7871 MVP Act
H.R. 7871 would lock in and refine Medicaid “value‑based” drug payment deals that tie what states pay to how well a medicine works, update how manufacturers report prices and refunds, add a narrow anti‑kickback safe harbor, and order a GAO study; it’s backed by managed‑care pharmacy and industry groups, while some child‑health and hospital advocates warn about costs shifting and new administrative burdens. (cms.gov)
Public Summary: Medicaid VBPs for Patients (MVP) Act — H.R. 7871 (119th)
Headline Summary: Lets state Medicaid programs strike “pay‑for‑results” deals on prescription drugs and clarifies price‑reporting rules so payments can track patient outcomes. (law.cornell.edu)
What It Does: The bill would codify value‑based purchasing (VBP) arrangements in Medicaid—agreements that link a drug’s net price to how well it works for patients—and make related updates to federal price‑reporting. In plain terms, it allows multiple “best price” points when a manufacturer offers the same VBP option to all states; clarifies how outcome‑based refunds and installment payments count in manufacturer price metrics; aligns a Medicare Part B pricing calculation so these outcome‑based refunds aren’t double‑counted; directs HHS to issue guidance so states can use VBPs even for certain inpatient drugs (including multi‑state coordination); creates a limited anti‑kickback safe harbor for VBP outcome‑based payments to states; and orders a Government Accountability Office study on access, outcomes, and costs. (Details come directly from the bill text you provided.)
- Managed‑care pharmacists (AMCP) say the MVP Act would help Medicaid cover high‑cost, high‑promise therapies (like some gene and cell treatments) by tying payment to patient outcomes. (amcp.org)
- The Council for Affordable Health Coverage supports the bill as a market‑based way to expand access while controlling spending. (cahc.net)
- The Institute for Gene Therapies backs the approach as a path to broader access to transformative therapies. (gene-therapies.org)
- In the Senate, a companion MVP Act (S. 1637) has been led by a bipartisan group including Sens. Hassan (D‑NH), Mullin (R‑OK), Sinema (I‑AZ), and Scott (R‑SC), signaling cross‑chamber interest. (hassan.senate.gov)
Who’s For It:
- Child and family health policy analysts at Georgetown CCF argue locking multiple “best prices” into law could raise costs for states that don’t or can’t use VBPs and create administrative complexity. (ccf.georgetown.edu)
- The American Hospital Association flagged provider burden and patient‑safety concerns if payment depends on prospective outcomes and extensive data tracking. (aha.org)
- Advocates in the 340B safety‑net community have raised concerns about how multiple‑best‑price policies might interact with 340B discounts and Medicaid rebates. (340breport.com)
- Academic analyses find VBPs can improve alignment of price with outcomes but also note real‑world transaction costs and challenges for smaller states and plans. (tandfonline.com)
Who’s Against It:
Why It Matters: For costly drugs where benefits can vary by patient, VBPs aim to protect Medicaid budgets and patients by refunding part of the price when a treatment under‑delivers—and rewarding proven results when it works. Supporters see faster access to breakthrough medicines and more predictable spending; critics worry about new red tape, uneven benefits across states, and pressure on safety‑net discounts. (cms.gov)
What’s Next: As of March 10, 2026, H.R. 7871 was introduced on March 9, 2026 and referred to the House Energy & Commerce Committee and the Ways & Means Committee. The next steps would typically be hearings and a committee markup before any House floor vote. (Status per the docket provided.)
Discussion